A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 332 participants.
Also called NCT01447147
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 332 participants
- Sponsor
- Registry
-
NCT01447147
-
- Other papers using this trial's data
- The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Czechia, Germany, Hungary, Poland, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01447147. Randomized; triple masking; primary purpose treatment. Start 2011-10 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Evaluate the Safety and Efficacy of CCX140-B in Subjects With Diabetic Nephropathy
- Condition
- Diabetic Nephropathy
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- Placebo
- Intervention (Drug)
- CCX140-B
- Intervention (Drug)
- CCX140-B
- Lead sponsor
- Amgen
Record details
- Record id
cardio:ct-nct01447147- Content hash
7ac39e8ef6783378c4c69276cd10d106aeb99b67f3c25f7665d4b952b6c22d8b